 FARMINGTON HILLS, Mich., April 06, 2022 GLOBE NEWSWIRE -- Ocuphire Pharma, Inc. Nasdaq: OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO, will review the opportunity for APX3330, a Phase 2b oral small molecule inhibitor of novel target Ref-1 in diabetic eye disease at the Wet AMD DME Drug Development Summit today, Wednesday, April 6 in Boston, MA. Ms. Sooch will also participate in a panel discussion titled, The Race to Market Share: Is the answer ending the burden of monthly treatments? Mitch Brigell, Ph.D., Head of Clinical Development and Strategy at Ocuphire, will moderate a panel discussion on Future Therapies Targeting Novel Mechanisms Driving Wet AMD DME at the Summit. 